Medibank Pvt Ltd (ASX: MPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medibank Pvt Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $10.30 billion
P/E Ratio 20.45
Dividend Yield 4.54%
Shares Outstanding 2.75 billion
Earnings per share 0.179
Dividend per share 0.17
Year To Date Return 12.53%
Earnings Yield 4.89%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Medibank Pvt Ltd (ASX: MPL)
    Latest News

    Stethoscope with a piggy bank and hundred dollar notes.
    Dividend Investing

    Hoping to bag the supersized Medibank dividend? You'd better be quick

    Medibank's latest dividend is a doozy...

    Read more »

    Cropped shot of an attractive young female scientist working on her computer in the laboratory.
    Healthcare Shares

    With a 6% yield, is this the best ASX healthcare share to buy for dividends?

    Is this category leader a healthy option for dividends?

    Read more »

    A woman stares at the candle on her cake, her birthday has fizzled.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 ended the week on a slightly sour note today.

    Read more »

    A women cheers with clenched fists having read some good news on her laptop.
    Share Gainers

    Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank shares are rising

    These shares are ending the week strongly. But why?

    Read more »

    Male doctor in a lab coat working at laptop looking serious.
    Earnings Results

    Medibank share price falls after FY24 result disappoints

    How did the health insurer perform? Let's find out.

    Read more »

    a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
    Share Market News

    5 things to watch on the ASX 200 on Thursday

    The Australian share market is expected to continue its winning streak today.

    Read more »

    Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
    Best Shares

    Which ASX 200 market sector has been the best performer over 10 years?

    This might surprise you...

    Read more »

    A woman's hand draws a stylised 'Top Ten' on a projected surface.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    ASX shares ran out of steam this Tuesday and finished lower...

    Read more »

    Shot of a mature scientists working on a laptop in a lab.
    Dividend Investing

    Medibank or NIB shares: Which one should you buy?

    Goldman Sachs has given its verdict on these two private health insurance giants.

    Read more »

    Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
    Dividend Investing

    Here's one way to invest $20k to target an average 7% ASX dividend yield

    Some businesses can provide high levels of dividend yield.

    Read more »

    Shot of a scientist using a computer while conducting research in a laboratory.
    Financial Shares

    Can Medibank shares expect a healthy FY25?

    It was a challenging period last financial year for the insurer.

    Read more »

    A man in a wheelchair stretches both arms into the air in success.
    Healthcare Shares

    Top broker says Medibank shares could return 19% in FY25

    This stock is predicted to produce healthy returns in FY25.

    Read more »

    Frequently Asked Questions

    Medibank Private was established by the Australian government in 1976 as a not-for-profit private health insurer. It converted into a for-profit entity in 2009 before listing on the ASX in November 2014.

    Yes, Medibank Private has paid dividends to shareholders every year since 2015. Typically, it pays an interim dividend in March and a final dividend in September, both fully franked.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    04 Sep 2024 $0.0940 100.00% Final 26 Sep 2024
    29 Feb 2024 $0.0720 100.00% Interim 20 Mar 2024
    13 Sep 2023 $0.0830 100.00% Final 05 Oct 2023
    02 Mar 2023 $0.0630 100.00% Interim 22 Mar 2023
    07 Sep 2022 $0.0730 100.00% Final 29 Sep 2022
    04 Mar 2022 $0.0610 100.00% Interim 24 Mar 2022
    08 Sep 2021 $0.0690 100.00% Final 30 Sep 2021
    03 Mar 2021 $0.0580 100.00% Interim 25 Mar 2021
    02 Sep 2020 $0.0630 100.00% Final 24 Sep 2020
    03 Mar 2020 $0.0570 100.00% Interim 26 Mar 2020
    04 Sep 2019 $0.0740 100.00% Final 26 Sep 2019
    05 Mar 2019 $0.0570 100.00% Interim 28 Mar 2019
    05 Sep 2018 $0.0720 100.00% Final 27 Sep 2018
    06 Mar 2018 $0.0550 100.00% Interim 28 Mar 2018
    06 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    07 Mar 2017 $0.0525 100.00% Interim 29 Mar 2017
    06 Sep 2016 $0.0600 100.00% Final 28 Sep 2016
    04 Mar 2016 $0.0500 100.00% Interim 29 Mar 2016

    MPL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Medibank Pvt Ltd

    Previously owned by the Australian government, Medibank Private Ltd (ASX: MPL) is the largest health insurer in Australia.

    As of November 2022, its two brands, Medibank Private and ahm, provide cover to almost five million people.

    Medibank and Australia's fourth-largest health fund, NIB Holdings Limited (ASX: NIB), are the only health insurers listed on the ASX.

    In addition to private health insurance, the company provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.

    MPL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 Nov 2024 $3.74 $0.05 1.36% 5,489,947 $3.71 $3.75 $3.69
    11 Nov 2024 $3.69 $-0.03 -0.81% 7,895,170 $3.72 $3.73 $3.69
    08 Nov 2024 $3.72 $0.04 1.09% 8,342,752 $3.70 $3.73 $3.68
    07 Nov 2024 $3.68 $0.03 0.82% 5,127,142 $3.68 $3.70 $3.65
    06 Nov 2024 $3.65 $0.05 1.39% 5,725,759 $3.61 $3.68 $3.58
    05 Nov 2024 $3.60 $-0.01 -0.28% 3,713,267 $3.59 $3.62 $3.58
    04 Nov 2024 $3.61 $0.06 1.69% 6,524,403 $3.61 $3.63 $3.56
    01 Nov 2024 $3.55 $-0.04 -1.11% 4,361,787 $3.57 $3.58 $3.53
    31 Oct 2024 $3.59 $-0.01 -0.28% 5,584,887 $3.60 $3.61 $3.55
    30 Oct 2024 $3.60 $-0.04 -1.10% 5,309,643 $3.63 $3.64 $3.59
    29 Oct 2024 $3.64 $0.00 0.00% 5,270,020 $3.64 $3.66 $3.62
    28 Oct 2024 $3.64 $-0.05 -1.36% 6,568,201 $3.69 $3.70 $3.64
    25 Oct 2024 $3.69 $0.01 0.27% 3,366,313 $3.68 $3.71 $3.68
    24 Oct 2024 $3.68 $-0.01 -0.27% 4,165,450 $3.70 $3.72 $3.68
    23 Oct 2024 $3.69 $0.02 0.54% 4,583,916 $3.67 $3.71 $3.67
    22 Oct 2024 $3.67 $-0.01 -0.27% 5,611,248 $3.66 $3.69 $3.64
    21 Oct 2024 $3.68 $0.02 0.55% 5,126,271 $3.69 $3.69 $3.66
    18 Oct 2024 $3.66 $-0.04 -1.08% 4,375,736 $3.70 $3.72 $3.65
    17 Oct 2024 $3.70 $0.04 1.09% 8,839,423 $3.72 $3.75 $3.69
    16 Oct 2024 $3.66 $-0.05 -1.35% 6,058,152 $3.70 $3.71 $3.66
    15 Oct 2024 $3.71 $0.03 0.82% 4,369,178 $3.70 $3.72 $3.68

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Sep 2024 David Koczkar Buy 457,907 $1,827,048
    Conversion of securities.
    02 Sep 2024 David Koczkar Expiry 260,942 $1,041,158
    As advised by the company. Lapsed,1,839,835 Rights
    02 Sep 2024 David Koczkar Exercise 457,907 $1,827,048
    Conversion of securities. 1,381,928 Rights
    26 Aug 2024 Jay Weatherill Buy 5,100 $19,915
    On-market trade.
    26 Aug 2024 Michael (Mike) Wilkins Buy 100,000 $396,000
    On-market trade.
    26 Aug 2024 Kathryn Fagg Buy 32,750 $129,362
    On-market trade.
    26 Feb 2024 Linda Nicholls Buy 5,400 $19,710
    On-market trade.
    11 Dec 2023 David Koczkar Issued 653,088 $2,292,338
    Issue of securities. 2,100,777 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael (Mike) John Wilkins Non-Executive DirectorNon-Executive Chairman May 2017
    Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He is a member of Investment and Capital and People Committee.
    Mrs Linda Bardo Nicholls Non-Executive Director Mar 2014
    Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is the Chair of the Investment and Capital Committee and also a member of Risk Management Committee.
    Ms Kathryn Joy Fagg Non-Executive Director Mar 2022
    Ms Fagg is a director and Chair with wide-ranging senior commercial and operational experience. She is a member of People Committee.
    Mr David Fagan Non-Executive Director Mar 2014
    Mr Fagan has practised as a commercial lawyer for over 40 years. During that time, he held a variety of leadership positions at Clayton Utz culminating in the role of Chief Executive Partner for 9 years. He is the Chair of the Risk Management Committee.
    Mr David Koczkar Chief Executive OfficerManaging Director May 2021
    Mr Koczkar has more than 25 years of strategy, innovation, commercial and operational experience across Australia, Asia and the UK, including previous work in the consulting and financial services industries.
    Mr Peter Dobie Everingham Non-Executive Director Mar 2022
    Mr Everingham has over 25 years of corporate experience and is highly respected in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes key roles at companies with a strong consumer and technology focus. He is a member of People and Investment and Capital Committee.
    Dr Tracey Leigh Batten Non-Executive Director Aug 2017
    Dr Batten has experience in the health services sector, with strong commercial, business and change leadership skills. She is the Chair of the People Committee and also a member of Risk Management Committee.
    Mr Gerard Dalbosco Non-Executive Director May 2021
    Mr Dalbosco held a number of senior leadership roles including Oceania Managing Partner and CEO; Asia Pacific Joint Deputy CEO and Managing Partner-Markets; Oceania Managing Partner-Transaction Advisory Services; and Melbourne Managing Partner. Prior to these roles Gerard advised organisations across a range of sectors in respect of merger and acquisitions advice, valuations, and strategic, commercial and financial due diligence. He is a member of Risk Management Committee.
    Mr Jay Wilson Weatherill Non-Executive Director Mar 2024
    Mr Weatherill has had a career in public office with expertise across a wide range of public policy areas including reform of social services. He is a member of Risk Management Committee.
    Ms Mei Ramsay Group General CounselCompany Secretary Mar 2011
    -
    Mei Ramsay Group General CounselCompany Secretary
    -
    Rob Read Group Lead Amplar Health
    -
    Milosh Milisavljevic Group Lead Chief Customer Officer
    -
    Mark Rogers Group Lead Chief Financial Officer & Group Strategy
    -
    Tom Exton Group Lead Chief Risk & Compliance Officer
    -
    Felicia Trewin Group Lead Data & Technology
    -
    Rob Deeming Group Lead Digital & Ventures
    -
    Kylie Bishop Group Lead People Spaces & Sustainability
    -
    Meaghan Telford Group Lead Policy Advocacy & Reputation
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 897,801,743 32.60%
    J P Morgan Nominees Australia Pty Limited 542,208,525 19.69%
    Citicorp Nominees Pty Limited 320,377,977 11.63%
    National Nominees Limited 81,375,680 2.95%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 71,271,047 2.59%
    BNP Paribas Noms Pty Ltd 46,314,124 1.68%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 21,450,620 0.78%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 20,002,248 0.73%
    HSBC Custody Nominees (Australia) Limited A/C 2 8,980,884 0.33%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 7,590,106 0.28%
    HSBC Custody Nominees (Australia) Limited i 7,343,069 0.27%
    Netwealth Investments Limited <Wrap Services A/C> 6,630,695 0.24%
    IOOF Investment Services Limited <Ips Superfund A/C> 5,169,307 0.19%
    UBS Nominees Pty Ltd 4,975,089 0.18%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 4,961,790 0.18%
    IOOF Investment Services Limited <Iisl Nal Isma 2 A/C> 3,786,900 0.14%
    Bond Street Custodians Limited <Cockej - F01832 A/C> 3,784,143 0.14%
    Ioof Investment Services Limited <Ioof Idps A/C> 3,745,418 0.14%
    Netwealth Investments Limited <Super Services A/C> 3,279,571 0.12%
    Solium Nominees (Australia) Pty Ltd <Vsa A/C> 3,221,313 0.12%

    Profile

    since

    Note